International Journal of Clinical Oncology

, Volume 13, Issue 1, pp 3–7

Update of evidence in chemotherapy for breast cancer

Authors

    • Department of Surgery and Oncology, Graduate School of MedicineKyoto University
  • Masakazu Toi
    • Department of Surgery and Oncology, Graduate School of MedicineKyoto University
Review Article

DOI: 10.1007/s10147-007-0719-1

Cite this article as:
Yamashiro, H. & Toi, M. Int J Clin Oncol (2008) 13: 3. doi:10.1007/s10147-007-0719-1

Abstract

Although recent progress in drug therapy has facilitated marked advances in chemotherapy for breast cancer, little has been achieved in the development of in dividualized chemotherapy. Prognostic factors such as estrogen receptor (ER), progesterone receptor (PgR), and human epithelial growth factor receptor 2 (HER2) have recently been incorporated into risk classification in the guidelines as predictive factors for treatment response, indicating that the treatment decisions for breast cancer have shifted to factors predictive of treatment response. For the selection of optimum adjuvant chemotherapy, the prediction of treatment responses and judgment of benefits and risks for individual patients are necessary, in addition to the guidelines, for which the investigation of clinical study results, the utilization of computer-based treatment decision tools, and gene profiling may be important.

Key words

IndividualizationChemotherapyMolecularProfiling
Download to read the full article text

Copyright information

© Japan Society of Clinical Oncology 2008